Tau Protein Targeting Antibody Pancreatic Cancer Innovation Therapy was shortlisted.

Drugs: Imatinib MMed Research: PHPrecisionMed Therapeutic diseases: Pulmonary arterial hypertension Introduction: imatenis (imatinib mesylate) imatinib, a small molecular inhibitor of anti-tumor tyrosine kinaseThe drug inhibits the activity of BCR-ABL, PDGFR, and c-KIT protein kinasesThese protein kinase-mediated signaling pathways are thought to be associated with the progression of pulmonary hypertensionImartinib has been used in clinical trials as an additional therapy for patients with pulmonary hypertensionDrugs: Huperzine A (SPN-817) Research and Development: Supernus Pharmaceuticals Treatment Of Diseases: Lennox-Gastaut Syndrome Introduction: Lennox-Gastaut syndrome (LGS) is a severe epileptic encephalopathy, accounting for about 1% to 2% of all epilepsy patients, mostly in childhood65% to 75% of LGS patients have identifiable factors such as hereditary, structural and metabolicHuperzine A is a small molecule inhibitor of acetylcholinesterase, representing a new anticonvulsive mechanismThe drug, which easily passes through the blood-brain barrier, increases levels of acetylcholine in the cerebral cortex and causes elevated levels of gamma-aminobutyric acid (GABA) in the cerebral cortex region, which can act as a suppression of seizuresIts activity has been validated in preclinical models of partial seizures and Dravet syndromeDrugs: PNT001 Research and Development: Pinteon Therapeutics Therapeutic Diseases: Conductive Nuclear Paralysis Introduction: Developed Nuclear Paralysis (PSP) is a rare brain disease that affects movement, balance and gait control, speech, swallowing, mood and behaviorSymptoms usually appear in the patient's 60s, slightly more men than in womenPinteon Therapeutics developed PNT001 as a monoclonal antibody that can be precisely targeted and binds to the cis-pT231 epitope of the Tau proteinTau proteins can be folded into different conformationsCis-p-tau is one of these highly neurotoxic conformationsThe spread of cis-p-tau and cis-p-tau and neurofibrosy of acute release is considered to be a potential driver of neuronal degeneration observed in traumatic brain injury (TBI), chronic traumatic encephalopathy (CTE), Alzheimer's disease (AD) and ongoing nuclear paralysis (PSP)This highly toxic cis-p-tau conformation exposes a binding site called cis-pT321d Preclinical data show that when antibodies bind to the epitopic, they block the acute and long-term effects of toxic tau and have the potential to improve the quality of life in patients with neurodegenerative diseases Drugs: Geranylgeranyanceusetone Research and Development: RNR BioMedical Therapeutic Diseases: Prevention of Liver Failure After Hepatothemy: Geranylgeranylacetone is a cyclogenic polyisopamate compound with a frame of viracel, which has been developed as an oral anti-ulcer drug in Japan It has the ability to protect the gastric mucous membranes from various stress-inducing injuries and is also a powerful inducing agent of the heat shock protein (HSPs) Heat shock proteins are induced by various environmental or physiological stresss (e.g heat, hypoxia, ischemia, and infection) within cells and play a key role in providing cell protection Last week, the U.S FDA just issued its orphan drug for the prevention of acute radiation syndrome Drugs: Proglumide Research and Development Agency: Georgetown University Treatment Diseases: Pancreatic Cancer Introduction: Proglumide is an oral active gallbladder shrinkin (CCK)-A/B receptor antagonist The drug can selectively block the role of CCK, has the ability to inhibit gastric fluid secretion and protect the gastric duodenum mucosa, but also has anti-epileptic and antioxidant activity The drug, once developed to treat stomach ulcers, has been tested for safety in humans Researchers at Georgetown University found in animal models that blocking CCK receptors reduces the growth of pancreatic cancer tumors, reduces fibrosis in the tumor microenvironment, and alters immune cell immersion to make tumors more sensitive to other therapies They plan to conduct Phase 1 clinical trials to explore the safety and dose of the drug as an anti-fibrosis treatment for pancreatic cancer patients Drugs: Tacrolimus Research and Development: TFF Pharmaceuticals Therapeutic Disease: Prevention of Lung Transplant Rejection Profile: This drug is an inhaled dry powder for his cromos, an immunosuppressive drug for solid organ transplantation Developed with TFF's thin-film freezing platform, TFF's process produces "brittle matrix particles" with low heap density (bulk density), high surface area and typical amorphous form, allowing particles to oversaturate contact target sites (e.g lung tissue) to improve the solubility and absorption of the drug The company plans to begin a phase 1 clinical study in Australia this month on the word dose of the oxmoth inhaler, with multiple incremental dose studies starting in the third quarter of this year